Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...

Grifols has shared positive results from its clinical trial evaluating the efficacy and safety of intravenous immunoglobulin to treat patients with PPS.

Carson Block of Muddy Waters announced Grifols (GRFS) as a short idea for the Robin Hood contest, according to Bloomberg.Light Up your ...

Muddy Waters CEO Carson Block picked Grifols (GRFS) as a short for the Robin Hood Foundation’s stock picking contest. However, said in an ...

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Learn more on GRFS stock here.

Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...

Activist hedge fund Gotham lambasted healthcare firm Grifols last year. Some of its key criticisms were vindicated. And its ...

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% ...

Grifols said it expects positive free cash flow to rise to €1.2-billion in 2029 and to €350 million-€400-million in 2025 after €266-million last year ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other ...